Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third ...
In his first interview after taking the reins of the FDA’s Oncology Center of Excellence (OCE), Angelo de Claro, M.D., is ...
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.
Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has ...
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...
In a series of moves by Switzerland-headquartered CDMOs this week, manufacturing powerhouse Lonza is doubling down on its US ...
Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...
Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...
Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...
In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark ...
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results